J 2013

Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment

SZTURZ, Petr; Zdeněk ADAM; Vladimír VAŠKŮ; Josef FEIT; Marta KREJČÍ et. al.

Basic information

Original name

Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment

Authors

SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution); Zdeněk ADAM (203 Czech Republic); Vladimír VAŠKŮ (203 Czech Republic, belonging to the institution); Josef FEIT (203 Czech Republic, belonging to the institution); Marta KREJČÍ (203 Czech Republic, belonging to the institution); Luděk POUR (203 Czech Republic, belonging to the institution); Roman HÁJEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2013, 1042-8194

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 2.605

RIV identification code

RIV/00216224:14110/13:00065629

Organization unit

Faculty of Medicine

DOI

UT WoS

000318806400035

Keywords in English

SCLEROMYXEDEMA; DEXAMETHASONE; ADULTORUM; BUSCHKE; THALIDOMIDE; DISORDERS; PATIENT; DISEASE

Tags

Tags

International impact, Reviewed
Changed: 31/10/2013 12:24, Soňa Böhmová

Abstract

V originále

Scleredema is a rare scleroderma-like fi bromucinosis characterized by progressive thickening of the skin caused by excessive collagen and mucin depositions in the dermis. Various treatment regimens have been proposed, however with inconsistent outcomes. Herein we are the fi rst to report a complete dermatological and hematological remission in a patient with multiple myeloma associated scleredema after bortezomib-based chemotherapy.

Links

GAP304/10/1395, research and development project
Name: Analýza klonálních progenitorů plazmatických buněk u monoklonálních gamapatií
Investor: Czech Science Foundation
MUNI/A/0784/2011, interní kód MU
Name: Nové diagnostické a klinické přístupy v onkologii (Acronym: NoDiKliPO)
Investor: Masaryk University, Category A
NT13190, research and development project
Name: Molekulární charakteristika centrozomálních abnormalit a jejich prognostický význam pro pacienty s mnohočetným myelomem
Investor: Ministry of Health of the CR
NT13492, research and development project
Name: Úloha genetických abnormalit ve vývoji a progresi prekancerózy monoklonální gamapatie nejasného významu